Detection and management of antiviral resistance for influenza viruses.
Neuraminidase inhibitors (NAIs) are first-line agents for the treatment and prevention of influenza virus infections. As for other antivirals, the development of resistance to NAIs has become an important concern particularly in the case of A(H1N1) viruses and oseltamivir. The most frequently reported change conferring oseltamivir resistance in that viral context is the H275Y neuraminidase mutation (N1 numbering). Recent studies have shown that, in the presence of the appropriate permissive mutations, the H275Y variant can retain virulence and transmissibility in some viral backgrounds. Most oseltamivir-resistant influenza A virus infections can be managed with the use of inhaled or intravenous zanamivir, another NAI. New NAI compounds and non-neuraminidase agents as well as combination therapies are currently in clinical evaluation for the treatment for severe influenza infections.
CHUQ-CHUL and Laval University, Quebec, QC, Canada.
Guy
G
Boivin
D000818:Animals; D000998:Antiviral Agents; D024882:Drug Resistance, Viral; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology; D014764:Viral Proteins / Q000235:genetics
D000998:Antiviral Agents; D014764:Viral Proteins
Antiviral; influenza; neuraminidase inhibitor; oseltamivir; resistance; zanamivir